Skadden, Davis Polk advise on 1st HK dual primary listing under new rules
BY Aparna Sai, Reuters |
Skadden, Arps, Slate, Meagher & Flom and Fangda Partners have counselled Chinese Nasdaq-listed biotech company BeiGene on its $903 million dual primary listing in Hong Kong, with Davis Polk & Wardwell and JunHe advising the joint sponsors and underwriters.